$9.23
(Market cap
$21,742 Mln
Revenue (TTM)
$14,144 Mln
P/E Ratio
23.5
P/B Ratio
2.4
Div. Yield
1.1 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$664 Mln
-
ROE
0.1 %
-
ROCE
5.6 %
-
Industry P/E
41.59
-
EV/EBITDA
13.3
-
Debt to Equity
0.7
-
Book Value
$--
-
EPS
$11.3
-
Face value
--
-
Shares outstanding
82,000,000
Years Aggregate
CFO
$--
EBITDA
$--
Net Profit
$--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Labcorp Holdings
| 8.1 | 6.7 | 0.6 | 6.8 | 12.7 | 3.9 | 9.2 |
|
BSE Sensex*
| -12.6 | -4.3 | -4.6 | -10.3 | 5.7 | 7.3 | 10.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
|---|---|---|
|
Labcorp Holdings
| 9.4 | 0.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 |
|
BSE Sensex
| 9.1 | 8.1 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Labcorp Holdings
|
271.2 | 21,742.3 | 14,144.2 | 941.5 | 9.8 | 10.8 | 23.5 | 2.4 |
| 97.1 | 120,983.4 | 407,905.0 | 2,932.0 | 1.6 | 3.9 | 41.6 | 1.5 | |
| 198.2 | 12,334.4 | 13,835.1 | 781.4 | 14.3 | -- | 18.5 | 91.7 | |
| 104.2 | 10,317.7 | 6,066.4 | 609.2 | 18.3 | 16.7 | 17.8 | 4.1 | |
| 374.9 | 80,268.3 | 76,388.0 | 6,794.0 | 15.8 | -- | 12.5 | 291.3 | |
| 29.0 | 6,483.1 | 2,369.7 | -13.2 | 1.3 | -2.6 | -- | 14.4 | |
| 204.5 | 22,171.4 | 11,278.0 | 1,024.0 | 13.4 | 13.3 | 22.1 | 3.0 | |
| 166.3 | 13,959.4 | 21,455.0 | 1,703.0 | 16.4 | 17.1 | 8.4 | 2.9 | |
| 155.3 | 9,953.3 | 5,274.0 | 363.4 | 9.2 | 16.2 | 27.8 | 4.2 | |
| 146.6 | 8,788.1 | 17,760.3 | 1,520.8 | 12.2 | 20.2 | 6.1 | 1.2 |
Shareholding Pattern
View DetailsAbout Labcorp Holdings
Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts,... thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, the company offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI-enabled Test Selection, a generative AI-enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. The company has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics. It also has a collaboration with Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer. The company was founded in 1995 and is headquartered in Burlington, North Read more
-
President, CEO & Chairman
Mr. Adam H. Schechter
-
President, CEO & Chairman
Mr. Adam H. Schechter
-
Headquarters
Burlington, NC
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Labcorp Holdings
What is the current share price of Labcorp Holdings Inc Today?
The share price of Labcorp Holdings Inc is $271.24 (NYSE) as of 09-Jun-2026 16:00 EDT. Labcorp Holdings Inc has given a return of 12.67% in the last 3 years.
What is the current PB & PE ratio of Labcorp Holdings Inc?
The P/E ratio of Labcorp Holdings Inc is 23.46 times as on 05-Jun-2026, a 44 discount to its peers’ median range of 41.59 times.
The P/B ratio of Labcorp Holdings Inc is 2.42 times as on 05-Jun-2026, a 18 discount to its peers’ median range of 2.95 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
23.81
|
2.42
|
|
2024
|
25.88
|
2.40
|
|
2023
|
46.16
|
2.45
|
|
2022
|
16.38
|
2.08
|
|
2021
|
12.71
|
2.94
|
What is the 52 Week High and Low of Labcorp Holdings Inc?
The 52-week high and low of Labcorp Holdings Inc are Rs 293.72 and Rs 241.81 as of 10-Jun-2026.
What is the market cap of Labcorp Holdings Inc?
Labcorp Holdings Inc has a market capitalisation of $ 21,742 Mln as on 05-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Labcorp Holdings Inc?
Before investing in Labcorp Holdings Inc, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.